PEPN1924, A Phase II Study of Trastuzumab Deruxtecan in Patients With Recurrent Human Epidermal Growth Factor Receptor 2+ Osteosarcoma: A Children's Oncology Group Pediatric Early-Phase Clinical Trial Network Study.

Saved in:
Bibliographic Details
Title: PEPN1924, A Phase II Study of Trastuzumab Deruxtecan in Patients With Recurrent Human Epidermal Growth Factor Receptor 2+ Osteosarcoma: A Children's Oncology Group Pediatric Early-Phase Clinical Trial Network Study.
Authors: Reed DR; Johns Hopkins All Children's Hospital, St. Petersburg, FL.; Moffitt Cancer Center, Tampa, FL., Janeway KA; Boston Children's Hospital, Boston, MA., Minard CG; Baylor College of Medicine, Houston, TX., Hall D; Children's Oncology Group, Monrovia, CA., Crompton BD; Dana-Farber cancer institute, Boston, MA., Lazar AJ; Anderson Cancer Center, Houston, TX., Wang WL; Anderson Cancer Center, Houston, TX., Zylber R; NYP/Columbia University Medical Center, New York, NY., Contreras A; Anderson Cancer Center, Houston, TX., Carrero G; Nicklaus Children's Hospital, Miami, FL., Voss SD; Dana-Farber cancer institute, Boston, MA., Reid JM; Mayo Clinic, Rochester, MN., Safgren SL; Mayo Clinic, Rochester, MN., Militano O; Children's Oncology Group, Monrovia, CA., Gorlick R; Anderson Cancer Center, Houston, TX., Pickett CA; National Cancer Institute, Bethesda, MD., Fox E; St Jude Children's Research Hospital, TN., Weigel BJ; University of Minnesota, Minneapolis, MN.
Source: JCO oncology advances [JCO Oncol Adv] 2025; Vol. 2. Date of Electronic Publication: 2025 Oct 14.
Publication Type: Journal Article
Journal Info: Publisher: Wolters Kluwer Health Country of Publication: United States NLM ID: 9918956761606676 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2994-9750 (Electronic) Linking ISSN: 29949750 NLM ISO Abbreviation: JCO Oncol Adv Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2994-9750
DOI:10.1200/oa-25-00094